Ebercit 1% Cream

Introduction

Ebercit is a prescription medication that contains the active ingredient Eberconazole. It is available in the form of a topical cream.

Uses

Ebercit is primarily used for the treatment of fungal infections of the skin, such as athlete’s foot (tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis). It works by stopping the growth of the fungus and reducing the associated symptoms, including itching, redness, and scaling.

Dosage and Administration

To use Ebercit, clean and dry the affected area before applying a thin layer of the cream. Gently rub it into the skin until it is completely absorbed. The cream is typically applied once or twice daily, as directed by your healthcare professional. Be sure to follow the dosage instructions provided by your healthcare professional.

Mechanism of Action

Eberconazole, the active ingredient in Ebercit, belongs to a class of medications called antifungals. It works by inhibiting the growth of the fungus responsible for the infection. By doing so, it helps to relieve the symptoms and promote healing of the affected skin.

Side Effects

Common side effects may include mild skin irritation, itching, or redness at the site of application. These side effects are usually mild and temporary.

However, if you experience any severe or persistent side effects, such as severe skin irritation, rash, or swelling, seek medical attention immediately. These may be signs of an allergic reaction or a more serious skin condition.

Drug Interactions

inform your healthcare professional about all the medications you are currently taking, including over-the-counter drugs, herbal supplements, and vitamins. There are no known significant drug interactions with Ebercit. However, it is always best to consult your healthcare professional to ensure the safe and effective use of this medication.

Precautions

Before using Ebercit, inform your healthcare professional if you have any known allergies to medications or any other substances. Additionally, let them know if you are pregnant, planning to become pregnant, or breastfeeding, as the safety of this medication during pregnancy and breastfeeding has not been established.

Avoid contact with eyes, mouth, or other mucous membranes while applying Ebercit. In case of accidental contact, rinse thoroughly with water. If your symptoms worsen or persist after using the cream, consult your healthcare professional.

Storage

Store Ebercit at room temperature, away from direct sunlight and heat. Keep it out of reach of children and pets. Do not freeze the cream. Always check the expiration date and discard any expired medication.

Patient Tips

• Follow the instructions provided by your healthcare professional regarding the application of Ebercit. Use it exactly as prescribed and for the recommended duration of treatment.
• Wash your hands before and after applying the cream to prevent the spread of infection.
• Keep the affected area clean and dry to enhance the effectiveness of the medication.
• If you miss a dose, apply it as soon as you remember. However, if it is close to the time for your next dose, skip the missed dose and continue with your regular dosing schedule.
• If your symptoms do not improve after a few weeks of treatment, or if they worsen, consult your healthcare professional for further evaluation.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Moodahadu-Bangera LS, Martis J, Mittal R, Krishnankutty B, Kumar N, Bellary S, Varughese S, Rao PK. Eberconazole–pharmacological and clinical review. Indian J Dermatol Venereol Leprol. 2012 Mar-Apr;78(2):217-22. doi: 10.4103/0378-6323.93651. [Accessed 29 Jun. 2024] Available at:
• del Palacio A, Ortiz FJ, Pérez A, Pazos C, Garau M, Font E. A double-blind randomized comparative trial: eberconazole 1% cream versus clotrimazole 1% cream twice daily in Candida and dermatophyte skin infections. Mycoses. 2001;44(5):173-80. doi: 10.1046/j.1439-0507.2001.00632.x. [Accessed 29 Jun. 2024] Available at:
• Barbanoj MJ, Antonijoan R, García-Gea C, Puntes M, Gich I, Jané F. Eberconazole cream: topical and general tolerability, sensitisation potential, and systemic availability. Methods Find Exp Clin Pharmacol. 2005 May;27(4):227-34. doi: 10.1358/mf.2005.27.4.893581. [Accessed 27 Jun. 2024] Available at:
• [No authors listed] Eberconazole. WAS 2160. Drugs R D. 1999 Feb;1(2):168-9. doi: 10.2165/00126839-199901020-00012. [Accessed 16 Jun. 2024] Available at: